

## Product Information

# Aprotinin from bovine lung

Lyophilized powder, 3-8 TIU/mg solid

**A1153**

## Product Description

CAS Registry Number: 9087-70-1

Synonyms: Basic pancreatic trypsin inhibitor, Bovine pancreatic trypsin inhibitor (BPTI), Kallikrein-trypsin inactivator, Kunitz protease inhibitor


Molecular formula:  $C_{284}H_{432}N_{84}O_{79}S_7$ 

Molecular weight: 6,512 Da

pI: 10.5

Extinction coefficient:  $E^{1\%} = 8.4$  (280 nm, water)

Aprotinin is a protein consisting of 58 amino acids, arranged in a single polypeptide chain that is cross-linked by three disulfide bridges (depicted below). Aprotinin is a competitive serine protease inhibitor that forms stable complexes with and blocks the active sites of various enzymes, such as those listed in Table 1. The binding is reversible. Most aprotinin-protease complexes dissociate at pH >10 or pH < 3.



Several theses<sup>1-3</sup> and dissertations<sup>4-16</sup> have cited use of product A1153 in their protocols.

## Reagent

Inhibitory Activity: 3-8 TIU/mg solid

Unit Definition: One Trypsin Inhibitor Unit (TIU) will decrease the activity of 2 trypsin units by 50%, where 1 trypsin unit will hydrolyze 1.0  $\mu$ mole of *N*- $\alpha$ -benzoyl-DL-arginine *p*-nitroanilide (BAPNA) per minute at pH 7.8 and 25 °C.

Another commonly used unit of activity is the KIU (Kallikrein Inhibitor Unit). Different conversion factors between aprotinin units have been reported:

- 1 TIU = 1,300 KIU
- 1 TIU = 1,025 KIU<sup>17</sup>

## Precautions and Disclaimer

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

## Preparation Instructions

Aprotinin is freely soluble in water (5 mg/mL) and in aqueous buffers of low ionic strengths.<sup>18</sup>

## Storage/Stability

Store the lyophilized powder at 2-8 °C. When stored at 2-8 °C, the product retains activity for at least 2 years.

Dilute solutions of aprotinin are generally less stable than concentrated ones. Solution stability is pH-dependent, although a pH range of 1-12 can be tolerated.<sup>19</sup> Repeated freeze-thaw cycles should be avoided.

The Cys<sup>14</sup>-Cys<sup>38</sup> disulfide bridge is readily split by reducing agents like 2-mercaptoethanol.<sup>19</sup> Due to its compact tertiary structure, aprotinin is relatively stable against denaturation due to high temperature, organic solvents, or proteolytic degradation (See Table 2). Only thermolysin has been found capable of degrading aprotinin after heating to 60-80 °C.<sup>19</sup>

The high basicity of aprotinin causes it to adhere to commonly used dialysis tubing and even gel filtration matrices. However, the use of acetylated materials and concentrated salt solutions (such as ≥ 0.1 M NaCl in buffer) minimizes this problem.<sup>19</sup>

Sterilization may be achieved by filtration through a 0.2 µm filter.

## References

1. Klopsch, Steven John, "Electrospray Ion Mobility – Time of Flight – Mass Spectrometry for the Detection of Inorganic Anions and Proteins in Aqueous Media". Washington State University, M.S. thesis, p. 55 (2007).
2. Kretschmar, Daniel Alan, "Purification of bacterially-expressed chick NSD3-SET that is active in an *in vitro* methyltransferase assay". University of Minnesota, M.S. thesis, p. 15 (2014).
3. Gratch, Yarden, "The Creation of Functional Pseudoislets Using Modular Tissue Engineering". University of Toronto, M.Sci. thesis, p. 16 (2020).
4. Robertson, Alexis, "Structural and functional studies of anosmin-1, the protein disrupted in X-linked Kallmann's syndrome". University of London, Ph.D. dissertation, p. 66 (2000).
5. Ayensu, Isaac, "Development of Novel Formulations for Mucosal Delivery of Protein Based Drugs". University of Greenwich, Ph.D. dissertation, p. 64 (2012).
6. Parker, Victoria Joanne, "Hypothalamic mechanisms mediating inhibition of prolactin secretion following stress in early pregnant mice". University of Edinburgh, Ph.D. dissertation, pp. 53, 61, 309 (2011).
7. Wuebben, Erin Lynn, "Altered Levels of SOX2, and its Associated Protein Musashi2, Disrupt Critical Cell Functions in Cancer and Embryonic Stem Cells". University of Nebraska Medical Center, Ph.D. dissertation, p. 47 (2016).
8. Chhabra, Nirav Florian, "Developmental gene *Pax6* in adult pancreas homeostasis and energy metabolism". Technischen Universität München, Dr. rer. nat. dissertation, p. 28 (2017).
9. Karki, Shanta, "Circadian Clock Regulation of Translation Initiation in *Neurospora crassa* Through Phosphorylation of a Highly Conserved Initiation Factor EIF2α". Texas A&M University, Ph.D. dissertation, p. 34 (2019).
10. Mitxitorena, Izaskun, "*In vitro* studies on the recognition of NF-κB p65 subunit by the deubiquitinase enzyme USP7". University of Glasgow, Ph.D. dissertation, p. 107 (2019).
11. Saleem, Umber, "Preclinical drug safety screening using induced pluripotent stem cell-derived cardiomyocytes in engineered heart tissue format". University of Hamburg, Dr. rer. nat. dissertation, p. 116 (Supplement) (2019).
12. Silvertown, Joshua Daniel, "Development and Characterization of an Adenoviral Vector Expressing Human H2 Relaxin". University of Guelph, Ph.D. dissertation, p. 166 (2019).
13. Zech, Antonia Theresa Luisa, "Investigation of the autophagy-lysosomal pathway in human inherited cardiomyopathies". University of Hamburg, Dr. rer. nat. dissertation, p. 149 (2019).
14. Keenen, Madeline Margaret, "Dissecting the mechanism of HP1 mediated chromatin compaction". University of California San Francisco, Ph.D. dissertation, p. 66 (2020).
15. Howard, Zachary M., "Mineralocorticoid and Glucocorticoid Signaling Differently Affect Skeletal Muscle Inflammation in Muscular Dystrophy". The Ohio State University, Ph.D. dissertation, p. 32 (2021).
16. Hult, Elissa Mairén Barhite, "The Role of M2 Macrophages and their Product, HB-EGF, as Regulators of Lung Fibrosis". University of Michigan, Ph.D. dissertation, p. 35 (2022).
17. Hewlett, G., *Biotechnology (NY)*, 565-566 (1990).
18. *Biochemica Information*, 1st ed. (J. Keesey, ed.). Boehringer Mannheim Biochemicals (Indianapolis, IN), p. 111 (1987).
19. Fritz, H., and Wunderer, G., *Arzneimittelforschung*, **33(4)**, 479-494 (1983).
20. Zollner, H. (ed.), *Handbook of Enzyme Inhibitors*, 2nd ed., Part B. VCH Verlagsgesellschaft (Weinheim, Germany), p. 572 (1993).
21. Kunitz, M., and Northrop, J.H., *J. Gen. Physiol.*, **19(6)**, 991-1007 (1936).
22. Sherman, M.P., and Kassell, B., *Biochemistry*, **7(10)**, 3634-3641 (1968).
23. Zyznar, E.S., *Life Sci.*, **28(17)**, 1861-1866 (1981).

**Table 1. Inhibition by Aprotinin**

<b>Enzyme (Source), Condition</b>	<b>Inhibition (K<sub>i</sub>)</b>
Acrosin	Weak inhibition <sup>18</sup>
Chymotrypsin	K <sub>i</sub> = 9 nM <sup>20</sup>
CMP- <i>N</i> -Acetyl-neuraminatate lactosylceramide α-2,3-sialyltransferase	74% Inhibition at 300 nM <sup>20</sup>
Elastase (human leukocyte), pH 8.0	K <sub>i</sub> = 3.5 μM <sup>19</sup>
Kallikrein (pancreatic), pH 8.0	K <sub>i</sub> = 1.0 nM <sup>19</sup>
Kallikrein (plasma)	K <sub>i</sub> = 30 nM; 100 nM <sup>18</sup>
Kallikrein (tissue)	K <sub>i</sub> = 1 nM <sup>18</sup>
Kallikrein (urine)	K <sub>i</sub> = 1.7 nM <sup>18</sup>
Plasmin (porcine), pH 7.8	K <sub>i</sub> = 4.0 nM <sup>19</sup>
Plasminogen activator	K <sub>i</sub> = 8 μM; 27 μM <sup>18</sup>
Trypsin (bovine), pH 8.0	K <sub>i</sub> = 0.06 pM <sup>19</sup>
Trypsinogen (bovine), pH 8.0	K <sub>i</sub> = 1.8 μM <sup>19</sup>
Tryptase TL-2	16% Inhibition at 10 μM <sup>18</sup>
Urokinase (human), pH 8.8	K <sub>i</sub> = 8.0 μM <sup>19</sup>

**Table 2. Aprotinin solution stability**

<b>Solvent</b>	<b>Concentration</b>	<b>Temperature</b>	<b>% Loss/Time</b>
Sterile water with 0.9% NaCl and 0.9% benzyl alcohol, pH 5.7-6.2	10 mg/mL	0-5 °C	< 4.3%/year
2.5% Trichloroacetic acid	N/A	80 °C	No loss <sup>21</sup>
pH < 12.6	N/A	N/A	No loss observed after 24 hours <sup>22</sup>
pH < 12	N/A	N/A	Irreversibly denatured <sup>23</sup>
pH 7-8	0.065-1.95 μg/mL	4 °C	About 1 week <sup>18</sup>
pH 7-8	0.065-1.95 μg/mL	-20 °C	> 6 months <sup>18</sup>

---

## Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

### Technical Assistance

Visit the tech service page at [SigmaAldrich.com/techservice](https://SigmaAldrich.com/techservice).

### Standard Warranty

The applicable warranty for the products listed in this publication may be found at [SigmaAldrich.com/terms](https://SigmaAldrich.com/terms).

### Contact Information

For the location of the office nearest you, go to [SigmaAldrich.com/offices](https://SigmaAldrich.com/offices).

The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.

MilliporeSigma, and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.  
© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

A1153pis Rev 06/22 RBG,MAC,GCY,MAM

The logo for MilliporeSigma, featuring the word "MILLIPORE" in a bold, red, sans-serif font above the word "SIGMA" in a similar bold, red, sans-serif font.